Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.
Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K. Hamada K, et al. Among authors: tsunoda t. Front Immunol. 2023 May 3;14:1164724. doi: 10.3389/fimmu.2023.1164724. eCollection 2023. Front Immunol. 2023. PMID: 37207204 Free PMC article.
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary.
Suzuki R, Hamada K, Ohkuma R, Homma M, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Ariizumi H, Kubota Y, Horiike A, Yoshimura K, Wada S, Yamochi T, Tsunoda T. Suzuki R, et al. Among authors: tsunoda t. Front Oncol. 2023 Jul 10;13:1231986. doi: 10.3389/fonc.2023.1231986. eCollection 2023. Front Oncol. 2023. PMID: 37496666 Free PMC article.
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: tsunoda t. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559573 Free PMC article.
Rapid Reduction of CEA and Stable Metastasis in an NRAS-mutant Rectal-Cancer Patient Treated With FOLFIRI and Bevacizumab Combined With Oral Recombinant Methioninase and a Low-Methionine Diet Upon Metastatic Recurrence After FOLFIRI and Bevacizumab Treatment Alone.
Kubota Y, Han Q, Morinaga S, Tsunoda T, Hoffman RM. Kubota Y, et al. Among authors: tsunoda t. In Vivo. 2023 Sep-Oct;37(5):2134-2138. doi: 10.21873/invivo.13310. In Vivo. 2023. PMID: 37652473 Free PMC article.
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: tsunoda t. Front Immunol. 2023 Sep 18;14:1260492. doi: 10.3389/fimmu.2023.1260492. eCollection 2023. Front Immunol. 2023. PMID: 37790929 Free PMC article.
1,165 results